HS-IT101

Cell therapy

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Non-Small Cell Lung Cancer · Phase 1Clear Cell Renal Cell Carcinoma · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Melanoma
Phase 1 (6)
Clear Cell Renal Cell Carcinoma
Melanoma
NCT06941818 · Hangzhou Huasai Biomedicine Co., Ltd.
2025-07-10 – 2026-10-01 · Advanced Melanoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06342336 · Hangzhou Huasai Biomedicine Co., Ltd.
2024-01-18 – 2028-03-31 · Solid Tumor
What this study did
NCT05505812 · The Affiliated Hospital of Qingdao University
2022-10-08 – 2027-03-31 · Breast Cancer
What this study did
NCT05539768 · The Affiliated Hospital of Qingdao University
2022-10-08 – 2027-03-31 · Advanced Solid Tumor
What this study did

Competitive landscape

Other Autologous tumor neoantigens (polyclonal, patient-specific) drugs

GC101. Compare all 2 Autologous tumor neoantigens (polyclonal, patient-specific) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Clear Cell Renal Cell Carcinoma: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HS-IT101: this drugPhase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
CasdatifanPhase 3Small moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
DarlifarnibPhase 1Small moleculeFarnesyltransferasenot yet gradedNo reviewed efficacy summary in this indication
XmAb819Phase 1Multispecific antibodyENPP3 x CD3not yet gradedNo reviewed efficacy summary in this indication
CTX131DiscontinuedCell therapyCD70not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HS-IT101 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07105176 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-12-31 · NCT07406724 · CT.gov ↗
What to watch
2028 (1)
August 2028 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2028-08 · NCT07770802 · CT.gov ↗
What to watch

See the full readout calendar ↗